CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $21.2M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
14.51BHKD1.85B · vs all stocks (USD)
Revenue (TTM)
166.25MHKD21.20M · vs all stocks (USD)
52-Week Change
-71.60%vs all stocks
Market Capitalization
14.51BHKD1.85B · vs all stocks (USD)
Enterprise Value
26.02BHKD3.32B · vs all stocks (USD)
Forward P/E
-17.97xvs Biotechnology peers
Price to Book (MRQ)
4.14xvs Biotechnology peers
Enterprise to Revenue
156.53xvs Biotechnology peers
Enterprise to EBITDA
-54.30xvs Biotechnology peers
Operating Margin
-257.46%vs Biotechnology peers
Return on Assets (TTM)
-129.39%vs Biotechnology peers
Return on Equity (TTM)
46.57%vs Biotechnology peers
Revenue (TTM)
166.25MHKD21.20M · vs all stocks (USD)
Revenue per Share (TTM)
0.1550HKDUpdated Aug 19, 2026Quarterly Revenue Growth
9.50%vs Biotechnology peers
Gross Profit (TTM)
88.86MHKD11.33M · vs all stocks (USD)
EBITDA (TTM)
-479.26MHKD-61.10M · vs all stocks (USD)
Net Income (TTM)
-598.12MHKD-76.25M · vs all stocks (USD)
Operating Cash Flow (TTM)
-243.31MHKD-31.02M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-92.33MHKD-11.77M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
10.32MUSDFY2024 · Dec 31, 2024Revenue
20.28MUSDFY2024 · Dec 31, 2024Cost of Goods Sold
11.40MUSDFY2024 · Dec 31, 2024Gross Profit
8.89MUSDFY2024 · Dec 31, 2024Operating Income
-67.31MUSDvs all stocks (USD)
Pre-tax Income
-95.64MUSDFY2024 · Dec 31, 2024Income Tax Expense
-3.43MUSDFY2024 · Dec 31, 2024Net Income
-92.21MUSDFY2024 · Dec 31, 2024EBIT
-81.34MUSDFY2024 · Dec 31, 2024EBITDA (Income Statement)
-63.46MUSDFY2024 · Dec 31, 2024Research & Development
19.10MUSDFY2024 · Dec 31, 2024Selling, General & Administrative
18.07MUSDFY2024 · Dec 31, 2024Non-operating Interest Income
25.33KUSDFY2024 · Dec 31, 2024Non-operating Interest Expense
14.30MUSDFY2024 · Dec 31, 2024EPS (Basic)
-0.3341USDFY2024 · Dec 31, 2024EPS (Diluted)
-0.3341USDFY2024 · Dec 31, 2024Basic Shares Outstanding
276.34MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
276.34MSharesFY2024 · Dec 31, 2024Minority Interests (P&L)
-112.27KUSDFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00USDFY2024 · Dec 31, 2024Operating Cash Flow
-58.99MUSDFY2024 · Dec 31, 2024Free Cash Flow
-60.43MUSDFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
5.07MUSDFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-95.64MUSDFY2024 · Dec 31, 2024Stock-based Compensation
15.49MUSDFY2024 · Dec 31, 2024Other Non-cash Items
14.46MUSDFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
6.94MUSDFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
-229.46KUSDFY2024 · Dec 31, 2024Capital Expenditures
-1.43MUSDFY2024 · Dec 31, 2024Net Intangibles (CF)
-52.35KUSDFY2024 · Dec 31, 2024Net Acquisitions
883.74KUSDFY2024 · Dec 31, 2024Purchase of Investments
-658.30KUSDFY2024 · Dec 31, 2024Other Investing Activity
-8.71MUSDFY2024 · Dec 31, 2024Net Investing Cash Flow
-9.92MUSDFY2024 · Dec 31, 2024Long-term Debt Issuance
26.48MUSDFY2024 · Dec 31, 2024Long-term Debt Payments
-61.31KUSDFY2024 · Dec 31, 2024Net Short-term Debt Issuance
0.00USDFY2024 · Dec 31, 2024Other Financing Charges
10.41MUSDFY2024 · Dec 31, 2024Net Financing Cash Flow
36.83MUSDFY2024 · Dec 31, 2024Shares Outstanding
276.34MSharesUpdated Aug 19, 2026Float Shares
81.30MSharesUpdated Aug 19, 2026% Held by Insiders
75.06%vs all stocks
% Held by Institutions
5.63%vs all stocks
Total Cash (MRQ)
850.24MHKD108.40M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3960HKDUpdated Aug 19, 2026Total Debt (MRQ)
181.65MHKD23.16M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2021xvs Biotechnology peers
Current Ratio (MRQ)
3.92xvs Biotechnology peers
Book Value per Share (MRQ)
3.00HKDUpdated Aug 19, 2026Total Assets
71.35MUSDvs all stocks (USD)
Total Current Assets
34.80MUSDFY2024 · Dec 31, 2024Total Liabilities
269.60MUSDFY2024 · Dec 31, 2024Total Non-current Assets
36.56MUSDFY2024 · Dec 31, 2024Total Non-current Liabilities
221.49MUSDFY2024 · Dec 31, 2024Total Current Liabilities
48.11MUSDFY2024 · Dec 31, 2024Cash
5.07MUSDFY2024 · Dec 31, 2024Cash & Cash Equivalents
5.07MUSDFY2024 · Dec 31, 2024Accounts Receivable
10.05MUSDFY2024 · Dec 31, 2024Inventory
4.50MUSDFY2024 · Dec 31, 2024Accounts Payable
5.19MUSDFY2024 · Dec 31, 2024Short-term Debt
22.58MUSDFY2024 · Dec 31, 2024Long-term Debt
10.12MUSDFY2024 · Dec 31, 2024Common Stock (Book)
1.33KUSDFY2024 · Dec 31, 2024Retained Earnings
-209.99MUSDFY2024 · Dec 31, 2024Total Shareholders' Equity
-198.24MUSDvs all stocks (USD)
Treasury Stock
131.00USDFY2024 · Dec 31, 202452-Week Low
12.28HKDUpdated Aug 19, 202652-Week High
77.30HKDUpdated Aug 19, 202652-Week Change
-71.60%vs all stocks
50-Day MA
12.41HKDUpdated Aug 19, 2026200-Day MA
25.36HKDUpdated Aug 19, 2026Avg 10-Day Volume
5.48MSharesUpdated Aug 19, 2026Avg 30-Day Volume
1.83MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-2.16HKDUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $21.2M, lower than 95% of all stocks globallySignificant
Revenue (USD): 21,195,026.62Global P5: 30,274,777.221
Market cap is $1.85B, above the global median of $1.15BNotable
Market cap (USD): 1,849,621,405.101Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novocure Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Edge Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guobang Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yifan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow